Novo Nordisk, a Denmark-based pharmaceutical company, is seeking a preliminary US court injunction to block Eli Lilly’s obesity and diabetes drug advertisements. The move is part of an escalating rivalry between the two companies in the obesity drug market, which is expected to be worth over $100 billion by the end of the decade in the US alone.
Background
Novo Nordisk announced on Tuesday that it had sued Eli Lilly, arguing that the company’s advertisements for its obesity drug Zepbound and diabetes treatment Mounjaro were misleading. Novo claimed that Lilly’s ads compared the highest approved doses of Zepbound and Mounjaro with lower doses of Novo’s Wegovy and Ozempic, omitting newer, higher-dose versions of Novo’s medicines that deliver greater weight loss.
Lilly has denied any wrongdoing and stated that it will vigorously defend itself against the lawsuit. The company has not commented on the preliminary injunction request.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
